Ziylo is a biotechnology company focusing on developing innovative glucose-responsive insulin products for diabetes management. The company utilizes a proprietary technology that allows insulin to be released in response to glucose levels, aiming to improve blood sugar control while minimizing the risk of hypoglycemia.